tradingkey.logo

Genfit SA

GNFT
4.850USD
0.0000.00%
交易中 美东报价延迟15分钟
242.51M总市值
--市盈率 TTM

Genfit SA

4.850
0.0000.00%

关于 Genfit SA 公司

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Genfit SA简介

公司代码GNFT
公司名称Genfit SA
上市日期Dec 19, 2006
CEOPrigent (Pascal)
员工数量180
证券类型Depository Receipt
年结日Dec 19
公司地址Parc Eurasante 885 avenue Eugene Avinee
城市LOOS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编59120
电话33320164000
网址https://www.genfit.fr/
公司代码GNFT
上市日期Dec 19, 2006
CEOPrigent (Pascal)

Genfit SA公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mrs. Anne-Helene Monsellato
Mrs. Anne-Helene Monsellato
Independent Director
Independent Director
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Eric Baclet
Mr. Eric Baclet
Independent Vice-Chairman of the Board of Directors
Independent Vice-Chairman of the Board of Directors
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
其他
99.88%
持股股东
持股股东
占比
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
其他
99.88%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
0.04%
Research Firm
0.04%
Investment Advisor
0.04%
其他
99.88%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
18
61.48K
0.12%
-644.21K
2025Q3
20
80.73K
0.16%
-686.95K
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
AllianceBernstein L.P.
22.36K
0.04%
+13.37K
+148.83%
Jun 30, 2024
Morgan Stanley & Co. International Plc
20.12K
0.04%
-7.30K
-26.62%
Sep 30, 2025
Summit Financial, LLC
18.75K
0.04%
+18.75K
--
Sep 30, 2025
Osaic Holdings, Inc.
225.00
0%
--
--
Sep 30, 2025
Principal Securities Inc
24.00
0%
--
--
Sep 30, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
--
0%
-1.00
-100.00%
Sep 30, 2025
Millennium Management LLC
--
0%
-131.48K
-100.00%
Jun 30, 2025
Lazard Asset Management, L.L.C.
--
0%
-3.30K
-100.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
--
0%
-3.21K
-100.00%
Nov 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI